Response Tailored Protocol Versus the Fixed 12 Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial

BACKGROUND: The most recent European Association for the Study of the Liver (EASL) 2016 Guidelines on treatment of hepatitis C (HCV), allowed for shortening the course of treatment for some subsets of patients with sofosbuvir/ledipasvir and with grazoprevir/elbasvir based on cutoff baseline HCV RNA...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:EBioMedicine
Päätekijät: Yakoot, Mostafa, Abdo, Alaa M., Abdel-Rehim, Siham, Helmy, Sherine
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2017
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5514382/
https://ncbi.nlm.nih.gov/pubmed/28647541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2017.05.011
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia